XyloCor Therapeutics Inc.
Biopharmaceuticals: Cardiovascular Disease/Gene Therapy
XyloCor Therapeutics is a biopharmaceutical company developing gene therapy for people with advanced coronary artery disease. The company is focused on developing its lead product, XC001, for patients with refractory angina with no treatment options. Its secondary product, XC002, is for patients with cardiac tissue damage from heart attacks. The company’s five year goals include successful clinical trials and the launch of XC001.
XyloCor Therapeutics was co-founded by a professor at Weill Cornell Medicine. It's foundational technology is licensed from Cornell University.